Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLU NASDAQ:HYPD NASDAQ:KLDO NASDAQ:PHXM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS Health$14.74$14.62$6.38▼$14.76$1.87B0.193.08 million shs3.45 million shsHYPDHyperion DeFi$7.08-14.3%$8.15$0.85▼$93.60$39.67M2.42914,650 shs376,612 shsKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.07$4K-0.0612,338 shs1,222 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%0.00%HYPDHyperion DeFi-14.29%-8.05%-55.25%+505.13%-92.92%KLDOKaleido Biosciences0.00%0.00%0.00%-95.00%0.00%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/AHYPDHyperion DeFi0.3655 of 5 stars1.00.00.00.02.20.80.6KLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS Health 0.00N/AN/AN/AHYPDHyperion DeFi 2.00Hold$2.00-71.75% DownsideKLDOKaleido Biosciences 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS Health$15K124,613.93N/AN/A$3.09 per share4.77HYPDHyperion DeFi$60K660.80N/AN/A($695.52) per share-0.01KLDOKaleido Biosciences$1.10M0.00N/AN/AN/A∞PHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/AHYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)KLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ALatest BLU, HYPD, PHXM, and KLDO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025HYPDHyperion DeFi-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/AHYPDHyperion DeFiN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS HealthN/A33.4233.42HYPDHyperion DeFiN/A0.340.34KLDOKaleido BiosciencesN/AN/AN/APHXMPHAXIAM Therapeutics0.231.78N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.37%HYPDHyperion DeFi25.84%KLDOKaleido Biosciences81.56%PHXMPHAXIAM Therapeutics0.40%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health24.17%HYPDHyperion DeFi10.86%KLDOKaleido Biosciences9.00%PHXMPHAXIAM Therapeutics1.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 million96.16 millionNot OptionableHYPDHyperion DeFi405.60 million5.00 millionOptionableKLDOKaleido Biosciences8042.62 million38.79 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataBLU, HYPD, PHXM, and KLDO HeadlinesRecent News About These CompaniesPHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJJuly 18, 2025 | wsj.comPhaxiam Therapeutics SA (PHXM) Stock Forums - Investing.comJune 27, 2025 | investing.comPHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until DelistingJune 18, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Judicial Liquidation and DelistingJune 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics: New Postponement of the Offer Review HearingJune 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Postponement of the Offer Review HearingMay 23, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Extension of the Observation Period of the Receivership ProcedureMay 5, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Update on the Receivership ProcedureApril 25, 2025 | finance.yahoo.comPhaxiam Therapeutics S.A.March 28, 2025 | wsj.comPHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership ProcedureMarch 15, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results PublicationMarch 6, 2025 | finance.yahoo.comPHAXIAM Therapeutics: Press Release Regarding Suspension of TradingMarch 6, 2025 | finance.yahoo.comPHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage TherapyJanuary 31, 2025 | businesswire.comPHAXIAM Therapeutics Announces Its Financial Calendar for 2025January 13, 2025 | finance.yahoo.comPHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in EuropeJanuary 7, 2025 | finance.yahoo.comPHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical StudyDecember 30, 2024 | finance.yahoo.comPHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaNovember 27, 2024 | globenewswire.comPHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"November 18, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | finanznachrichten.dePHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonDon’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonBy Chris Markoch | July 8, 2025View Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings SeasonPepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?By Thomas Hughes | July 19, 2025View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?PEGA Surges 14%: There's Still Time to Ride This GenAI InnovatorBy Leo Miller | July 27, 2025View PEGA Surges 14%: There's Still Time to Ride This GenAI InnovatorBLU, HYPD, PHXM, and KLDO Company DescriptionsBELLUS Health NASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Hyperion DeFi NASDAQ:HYPD$7.08 -1.18 (-14.29%) As of 08/1/2025 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Kaleido Biosciences NASDAQ:KLDO$0.0001 0.00 (0.00%) As of 08/1/2025 09:34 AM EasternKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 08/1/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
